The glucocorticoid receptor interacting protein 1 (GRIP1) localizes in discrete nuclear foci that associate with ND10 bodies and are enriched in components of the 26S proteasome

被引:88
作者
Baumann, CT
Ma, H
Wolford, R
Reyes, JC
Maruvada, P
Lim, C
Yen, PM
Stallcup, MR
Hager, GL
机构
[1] NCI, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20892 USA
[2] NIDDKD, Mol Regulat & Neuroendocrinol Sect, Clin Endocrinol Branch, NIH, Bethesda, MD 20892 USA
[3] Univ So Calif, Dept Pathol, Los Angeles, CA 90033 USA
关键词
D O I
10.1210/me.15.4.485
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The glucocorticoid receptor interacting protein-1 (GRIP1) is a member of the steroid receptor coactivator (SRC) family of transcriptional regulators. Green fluorescent protein (GFP) fusions were made to full-length GRIP1, and a series of GRIP1 mutants lacking the defined regulatory regions and the intracellular distribution of these proteins was studied in HeLa cells. The distribution of GRIP1 was complex, ranging from diffuse nucleoplasmic to discrete intranuclear foci. Formation of these foci was dependent on the C-terminal region of GRIP1,which contains the two characterized transcriptional activation domains, AD1 and AD2. A subpopulation of GRIP1 foci associate with ND10s, small nuclear bodies that contain several proteins including PML, SP100, DAXX, and CREB-binding protein (CBP). Association with the ND10s is dependent on the AD1 of GRIP1, a region of the protein previously described as a CBP-interacting domain. The GRIP1 foci are enriched in components of the 26S proteasome, including the core 20S proteasome, PA28 alpha, and ubiquitin. In addition, the irreversible proteasome inhibitor lactacystin induced an increase in the total fluorescence intensity of the GFP-GRIP1 expressing cells, demonstrating that GRIP1 is degraded by the proteasome. These findings suggest the intriguing possibility that degradation of GRIP1 by the 26S proteasome may be a key component of its regulation.
引用
收藏
页码:485 / 500
页数:16
相关论文
共 84 条
[1]   Proteasome-mediated proteolysis of estrogen receptor: A novel component in autologous down-regulation [J].
Alarid, ET ;
Bakopoulos, N ;
Solodin, N .
MOLECULAR ENDOCRINOLOGY, 1999, 13 (09) :1522-1534
[2]   The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein [J].
Alcalay, M ;
Tomassoni, L ;
Colombo, E ;
Stoldt, S ;
Grignani, F ;
Fagioli, M ;
Szekely, L ;
Helin, K ;
Pelicci, PG .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (02) :1084-1093
[3]   Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation [J].
Alessandrini, A ;
Chiaur, DS ;
Pagano, M .
LEUKEMIA, 1997, 11 (03) :342-345
[4]   Intracellular localization of proteasomal degradation of a viral antigen [J].
Antón, LC ;
Schubert, U ;
Bacík, I ;
Princiotta, MF ;
Wearsch, PA ;
Gibbs, J ;
Day, PM ;
Realini, C ;
Rechsteiner, MC ;
Bennink, JR ;
Yewdell, JW .
JOURNAL OF CELL BIOLOGY, 1999, 146 (01) :113-124
[5]   AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer [J].
Anzick, SL ;
Kononen, J ;
Walker, RL ;
Azorsa, DO ;
Tanner, MM ;
Guan, XY ;
Sauter, G ;
Kallioniemi, OP ;
Trent, JM ;
Meltzer, PS .
SCIENCE, 1997, 277 (5328) :965-968
[6]   Intracellular localization and trafficking of steroid receptors [J].
Baumann, CT ;
Lim, CS ;
Hager, GL .
CELL BIOCHEMISTRY AND BIOPHYSICS, 1999, 31 (02) :119-127
[7]  
BAUMANN CT, IN PRESS J BIOL CHEM
[8]   Regulation of the G1 phase of the cell cycle by periodic stabilization and degradation of the p25rum1 CDK inhibitor [J].
Benito, J ;
Martín-Castellanos, C ;
Moreno, S .
EMBO JOURNAL, 1998, 17 (02) :482-497
[9]  
Boudjelal M, 2000, CANCER RES, V60, P2247
[10]   Posttranslational modification of Bcl-2 facilitates its proteasome-dependent degradation: Molecular characterization of the involved signaling pathway [J].
Breitschopf, K ;
Haendeler, J ;
Malchow, P ;
Zeiher, AM ;
Dimmeler, S .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (05) :1886-1896